ScreenerHero

KRRO Korro Bio, Inc.

NAS · US · Healthcare · Biotechnology · korrobio.com
10.49USD+7.48%Mkt Cap: 154.47M $P/E: —

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United St…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap154.47M USD
Enterprise Value70.90M USD
Revenue (TTM)2.38M USD
Gross Profit-41.02M USD
Net Income (TTM)-117.26M USD
Revenue/Share0.20 USD
Last Price10.49 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees57
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.19
PEG—
EV/EBITDA-0.95
EV/Revenue29.76
P/S60.34
P/B1.39
EPS (TTM)-9.88
EPS (Forward)-4.46
52W Range
5.20410% of range55.89
52W High55.89 USD
52W Low5.204 USD
Profitability
Gross Margin0.00%
Oper. Margin-3228.34%
EBITDA Margin0.00%
Profit Margin-1834.48%
ROE-227.96%
ROA-103.31%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-78.56M USD
CapEx (TTM)518.00K USD
FCF Margin-1737.62%
FCF Yield-26.79%
Net Debt-72.82M USD
Net Debt/EBITDA0.98
Balance Sheet
Debt/Equity0.85
Current Ratio9.55
Quick Ratio9.11
Book Value/Sh7.02 USD
Cash/Share7.81 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateNov 6, 2023
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)20.20 USD
Upside (mean)+92.6%
Target Range10.00 USD – 30.00 USD
10.00+92.6% to mean30.00
# Analysts10
Ownership
Shares Out.14.73M
Float10.58M
Insiders0.89%
Institutions105.23%
Short Interest
Short Ratio15.4d
Short % Float11.80%
Short % Out.10.54%
Shares Short1.55M
Short (prev mo.)1.51M
Technical
SMA 5011.92 (-12.0%)
SMA 20011.70 (-10.3%)
Beta2.36
S&P 52W Chg16.45%
Avg Vol (30d)156.47K
Avg Vol (10d)143.76K
Technical Indicators
RSI (14)46.1
MACD-0.6815
MACD Signal-0.6864
MACD Hist.+0.0049
BB Upper14.50 USD
BB Middle10.96 USD
BB Lower7.414 USD
BB Width64.66%
ATR (14)0.8885 USD
Vol Ratio (20d)0.81x